Search Results - "Quinlin, Imelda S"

MHC-Unrestricted Lysis of MUC1-Expressing Cells by Human Peripheral Blood Mononuclear Cells by Wright, Stephen E., Rewers-Felkins, Kathleen A., Quinlin, Imelda S., Fogler, William E., Phillips, Catherine A., Townsend, Mary, Robinson, William, Philip, Ramila

“…Many human adenocarcinomas can be killed in vitro by targeted cytotoxic T-lymphocytes (CTL); however, major histocompatibility complex (MHC)-restrictions are…”
Get full text

Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate “Natural” and “Inducible” CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer by Dobrzanski, Mark J., Rewers-Felkins, Kathleen A., Samad, Khaliquzzaman A., Quinlin, Imelda S., Phillips, Catherine A., Robinson, William, Dobrzanski, David J., Wright, Stephen E.

“…Adoptive T cell therapy for cancer patients optimally requires participation of CD4 T cells. In this phase I/II study, we assessed the therapeutic effects of…”
Get full text

Cytotoxic T-lymphocyte Immunotherapy for Ovarian Cancer: A Pilot Study by WRIGHT, Stephen E, REWERS-FELKINS, Kathleen A, QUINLIN, Imelda S, PHILLIPS, Catherine A, TOWNSEND, Mary, PHILIP, Ramila, DOBRZANSKI, Mark J, LOCKWOOD-COOKE, Pamela R, ROBINSON, William

“…The objective was to evaluate the toxicity and feasibility of intraperitoneal infusion of tumor-specific cytotoxic T lymphocytes (CTL) as therapy for recurrent…”
Get full text

Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival by Dobrzanski, Mark J, Rewers-Felkins, Kathleen A, Quinlin, Imelda S, Samad, Khaliquzzaman A, Phillips, Catherine A, Robinson, William, Dobrzanski, David J, Wright, Stephen E

“…Abstract Adoptive T cell immunotherapy using autologous lymphocytes is a viable treatment for patients with cancer and requires participation of Ag-specific…”
Get full text

Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer by Wang, Zhenyao, Hall, Monte D., Rewers-Felkins, Kathleen A., Quinlin, Imelda S., Wright, Stephen E.

“…Dendritic cells (DCs) are among the most potent antigen-presenting cells (APCs), stimulating peripheral blood mononuclear cells (PBMCs) to generate…”
Get full text

Tumor Burden Influences Cytotoxic T Cell Development in Metastatic Breast Cancer Patients-A Phase I II Study by Wright, Stephen E., Rewers-Felkins, Kathleen A., Quinlin, Imelda S., Phillips, Catherine A., Townsend, Mary, Philip, Ramila, Zorsky, Paul, Klug, Panpit, Dai, Lijun, Hussain, Mohammad, Thomas, Aabu A., Sundaramurthy, Chithraleka

“…The influence of tumor burden on the generation of tumor antigen-specific cytotoxic T-lymphocytes (CTL) was investigated in a phase I II clinical adoptive…”
Get full text

Number of Treatment Cycles Influences Development of Cytotoxic T Cells in Metastatic Breast Cancer Patients - A Phase I II Study by Wright, Stephen E., Rewers-Felkins, Kathleen A., Quinlin, Imelda S., Phillips, Catherine A., Townsend, Mary, Philip, Ramila, Zorsky, Paul, Klug, Panpit, Dai, Lijun, Hussain, Mohammad, Thomas, Aabu A., Sundaramurthy, Chithraleka

“…The influence of the number of apheresis-stimulation-infusion(s) cycles, and the time in culture before the infusion (one vs. two weeks), on the generation of…”
Get full text

Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells by Wright, Stephen E, Rewers-Felkins, Kathleen A, Quinlin, Imelda S, Eldridge, Paul W, Zorsky, Paul E, Klug, Panpit P, Phillips, Catherine A, Philip, Ramila

“…Mucin1 stimulated hematopoietic mononuclear cells (M1SHMC) from patients with breast cancer, adoptively transferred to non-obese diabetic, severe combined…”
Get more information

Immunotherapy with IL-10- and IFN-[gamma]-producing CD4 effector cells modulate "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer by Dobrzanski, Mark J, Rewers-felkins, Kathleen A, Samad, Khaliquzzaman A, Quinlin, Imelda S, Phillips, Catherine A, Robinson, William, Dobrzanski, David J, Wright, Stephen E

“…Adoptive T cell therapy for cancer patients optimally requires participation of CD4 T cells. In this phase I/II study, we assessed the therapeutic effects of…”
Get full text

Autologous MUC1-Specific Th1 Effector Cell Immunotherapy Induce Differential Levels of Systemic TReg Cell Subpopulations That Result in Increased Ovarian Cancer Patient Survival by Dobrzanski, Mark J., Rewers-Felkins, Kathleen A., Quinlin, Imelda S., Samad, Khaliquzzaman A., Phillips, Catherine A., Robinson, William, Dobrzanski, David J., Wright, Stephen E.

“…Adoptive T cell immunotherapy using autologous lymphocytes is a viable treatment for patients with cancer and requires participation of Ag-specific CD4 and CD8…”
Get full text

Autologous MUC1-specific Th 1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival by DOBRZANSKI, Mark J, REWERS-FELKINS, Kathleen A, QUINLIN, Imelda S, SAMAD, Khaliquzzaman A, PHILLIPS, Catherine A, ROBINSON, William, DOBRZANSKI, David J, WRIGHT, Stephen E

Get full text

Retention of immunogenicity produced by mucin1 peptides with glycosylation site substitutions by Wright, Stephen E., Quinlin, Imelda S., Rewers-Felkins, Kathleen A., Dombrowski, Ken E., Phillips, Catherine A.

“…Mucin1 (MUC1) with altered glycosylation behaves as an antigen unique to adenocarcinomas (ADCs). As a step toward DNA vaccines, the goal of this work was to…”
Get full text

Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutions by Wright, Stephen E, Quinlin, Imelda S, Rewers-Felkins, Kathleen A, Dombrowski, Ken E, Phillips, Catherine A

“…Mucin1 (MUC1) with altered glycosylation behaves as an antigen unique to adenocarcinomas (ADCs). As a step toward DNA vaccines, the goal of this work was to…”
Get full text